LEARNING OBJECTIVES
After participating in this program, the learner will be better able to:
UNDERSTANDING THE DIAGNOSIS AND TREATMENT OF PULMONARY ARTERIAL HYPERTENSION
-
Describe the process for the differential diagnoses of pulmonary hypertension (PH) and pulmonary arterial hypertension (PAH)
-
List key echocardiographic features that may indicate PAH
-
Explain the role for right heart catheterization in the diagnosis of PAH
-
Discuss the current definition of PAH
-
Review the classification of pulmonary hypertension according to the 2013 Nice Guidelines
-
Utilize currently available medical treatments, strategies, and goals for PAH treatment
20 YEARS OF PROSTANOIDS: SPANNING THE CONTINUUM OF CARE IN PAH
-
Discuss the role of prostacyclin in the etiology of PAH
-
Explain the current positioning of prostanoids in the PAH treatment algorithm proposed by the ACCP
-
Outline the fundamental findings from pivotal studies of currently approved prostanoids in PAH and in hard-to-treat patients
-
Describe perceived barriers to the use of prostanoids in modern practice leading to underutilization
-
Review recent new prostanoid formulations and emerging PC analogs, their use in mono- and combination-therapy
-
Explain the benefits of prostanoid use, alone and in combination, to improve morbidity and mortality across the spectrum of PH severity
GROUP 1 AND BEYOND: CASE STUDIES IN PULMONARY HYPERTENSION
-
Describe the signs and symptoms of pulmonary hypertension
-
Discuss the most current diagnostic algorithm for pulmonary hypertension
-
Compare the key diagnostic tests for pulmonary hypertension and the role of right heart catheterization in confirming PH diagnosis
-
Differentiate between left heart disease, PH due to left heart disease, and pulmonary arterial hypertension
-
Discuss the current treatment algorithm for pulmonary hypertension and the available treatments
DATE:
|
TIME:
|
COST:
|
LOCATION:
|
RSVP DEADLINE:
|
Friday, September 9, 2016
|
8:00 AM - 11:00 AM
|
Free
|
The Roosevelt Hotel, 45 East 45th Street @ Madison Avenue, New York, NY |
Friday, August 26, 2016
|
DATE:
|
TIME:
|
COST:
|
LOCATION:
|
RSVP DEADLINE:
|
Friday, September 30, 2016
|
8:00 AM - 11:00 AM
|
Free
|
Hilton Chicago, 720 South Michigan Avenue, Chicago, IL |
Friday, September 9, 2016
|
FACULTY
-
Richard Channick, MD
-
Paul Forfia, MD
-
Nick H. Kim, MD
-
Roberto Machado, MD
-
Vallerie McLaughlin, MD
- Rajan Saggar, MD
-
Robert Schilz, DO, PhD
- Sean Studer, MD, MSc
- Roxana Sulica, MD
- Victor F. Tapson, MD
PHYSICIAN CONTINUING MEDICAL EDUCATION
Accreditation Statement: This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education
(ACCME) through the joint providership of Postgraduate Institute for Medicine and TotalCME. The Postgraduate Institute for Medicine is accredited by the ACCME to provide continuing medical
education for physicians.
Credit Designation:
The Postgraduate Institute for Medicine designates this live activity for a maximum of 3.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with
the extent of their participation in the activity.
NURSING CONTINUING EDUCATION
This educational activity for 3.0 contact hours is provided by Postgraduate Institute for Medicine. Postgraduate Institute for Medicine is accredited as a provider of continuing nursing education by the
American Nurses Credentialing Center’s Commission on Accreditation.
California Board of Registered Nursing: Provider approved by the California Board of Registered Nursing, Provider Number 13485, for 3.0 contact hours.
DISCLOSURE OF CONFLICTS OF INTEREST
Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict
of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. The existence or absence of COI for everyone in a
position to control content will be disclosed to participants prior to the start of each activity.
This activity has been designed to meet the educational needs of physicians, registered nurses and other healthcare professionals involved in the care of patients with pulmonary arterial hypertension (PAH).
This activity is supported by independent educational grants from Actelion Pharmaceuticals US, Inc. and Arena Pharmaceuticals, Inc.
A statement of credit will be issued only upon receipt of a completed activity evaluation form and will be emailed to participants within three weeks.
Americans with Disabilities Act:Event staff will be glad to assist you with any special needs (ie, physical, dietary, etc). Please contact Julie Krantz prior to the live event at (888) 391-3996.